Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Biotechnology

Healthcare
$61.99 -1.39%

-$0.46 today

Market cap
$1.79B
Beta
0.89
P/E (TTM)
-597.6
EPS (TTM)
-$0.05
52W Low $13.09High $35.66

Volume 0.48M

Average 0.43M

ETON Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Eton Pharmaceuticals, Inc.NASDAQ: ETON

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 60.7%

Gross margin was 60.7% in Q1 FY2026, up 3.7 pp from a year earlier. On a trailing-twelve-month basis it was 54.8%, down 3.7 pp year over year. Over 3 fiscal years it narrowed by 13.9 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
60.7%-0.8 pp QoQ
Last fiscal yearDec 2025
53.5%-6.6 pp YoY
LTMMar 2026
54.8%-3.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.7 pp——
1 year-6.6 pp——
3 years-13.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
53.5%
Year-over-year change
-6.6pp

Gross Margin vs competitors

How ETON compares with its peers on the latest reported figures

  • ETON's LTM Mar 2026 gross margin of 54.8% is the lowest of the 8 companies compared; the peer median is 87.3%.
  • Its year-over-year change of -3.7 pp is the 7th highest of 8, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -13.9 pp compares with a peer median of -2.8 pp.
ETON Competitors Peer median
Gross Margin for ETON and competitors
Company Period LTM level YoY 3-year change
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 202699.1% +83.0 pp+37780.7 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 202698.2% -0.6 pp+0.7 pp
FENCFennec Pharmaceuticals Inc.LTM Mar 202692.2% +2.0 pp-2.8 pp
PHARPharming Group N.V.LTM Mar 202687.3% -1.7 pp-3.6 pp
ZVRAZevra Therapeutics, Inc.LTM Mar 202685.5% +6.7 pp-13.3 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
TVTXTravere Therapeutics, Inc.LTM Sep 202660.7% -37.0 pp+1.9 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 202654.8% -3.7 pp-13.9 pp
DMACDiaMedica Therapeutics Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
Peer median (excluding ETON) 87.3%-0.6 pp-2.8 pp

Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.83M21.25M31.64M39.01M79.95M
Cost of Revenue2.62M6.93M10.58M15.6M37.21M
Gross Profit19.21M14.32M21.06M23.41M42.74M
Gross Margin88.0%67.4%66.6%60.0%53.5%
Research & Development6.24M4M3.32M3.26M7.77M
Selling, General & Admin14.47M18.58M18.93M22.75M35.82M
Operating Expenses20.7M22.58M22.25M26.01M42.67M
Depreciation & Amortization462K1.77M901K1.15M4.04M
EBITDA(1.49M)(7.25M)212K(657K)4.27M
EBITDA Margin-6.8%-34.1%0.7%-1.7%5.3%
Operating Income(1.5M)(8.26M)(1.19M)(2.6M)72K
Operating Margin-6.8%-38.9%-3.8%-6.7%0.1%
Interest Income00000
Interest Expense1.04M955K1.06M2.01M4.78M
Other Income / Expenses(460K)(761K)503K(1.21M)(4.63M)
Income Before Tax(1.96M)(9.02M)(689K)(3.81M)(4.56M)
Pre-Tax Margin-9.0%-42.4%-2.2%-9.8%-5.7%
Income Tax Expense00247K15K43K
Net Income(1.96M)(9.02M)(936K)(3.82M)(4.6M)
Net Margin-9.0%-42.4%-3.0%-9.8%-5.8%
EPS (Basic)(0.08)(0.36)(0.04)(0.15)(0.17)
EPS (Diluted)(0.08)(0.36)(0.04)(0.15)(0.17)
Weighted Avg Shares25.21M25.15M25.65M25.9M26.91M
Weighted Avg Shares (Diluted)25.21M25.15M25.65M25.9M26.91M

Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Intrinsic Alpha fair value

Locked

Current Price

$61.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.